Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

Strike three for Rova-T has AbbVie cutting its losses

Strike three for Rova-T has AbbVie cutting its losses

The drugmaker acquired Rova-T via its $9.8bn takeover of  Stemcentrx three years ago, on the back of encouraging mid-stage clinical data with the drug in small cell lung ... At the time of the Stemcentrx acquisition Rova-T had been tipped as a possible

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:. ... Licensor/Acquisition target. Licensee/Acquirer. Deal type. Product technology. Headline $m. Stemcentrx (US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....